第一至尊娱乐平台网主办
»您现在的位置: 第一至尊娱乐平台网 >> 至尊娱乐平台焦点 >> 文传商讯 >> 正文

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

2019/9/4 16:41:25  文章来源:文传商讯  作者:文传商讯
文章简介: BoehringerIngelheimstrengthensitspipelineportfolioforpatientswithgastrointestinalandlungcancerswiththisnewlicensing,developmentandcommer

Boehringer Ingelheim strengthens its pipeline portfolio for patients with gastrointestinal and lung cancers with this new licensing, development and commercialization agreement
Lupin’s proprietary MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s emerging KRAS inhibitor pipeline to address KRAS-driven cancers
Lupin to receive a $20 million upfront payment with potential total milestones of more than $700 million and royalties on the sales of the product

INGELHEIM, Germany & MUMBAI, India--(BUSINESS WIRE)--Boehringer Ingelheim and Lupin Limited (Lupin) today announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin’s lead MEK inhibitor compound in combination with one of Boehringer Ingelheim’s innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.

“The licensing of Lupin’s novel MEK inhibitor enables us to pair with our innovative KRAS inhibitors to develop new combination treatment concepts providing more effective and durable responses for patients with cancers driven by activated KRAS who currently have limited treatment options available,” said Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim. “We believe this collaboration will significantly strengthen our KRAS program. We have developed comprehensive approaches to successfully tackle the oncogenic KRAS–RAF–MEK–ERK pathway from the ground up and this partnership is another key building block in our long-term strategy to bring novel treatments to patients in our quest to defeat intractable cancer types.”

Commenting on the partnership, Nilesh Gupta, Managing Director, Lupin Limited said, “With the success of our second new drug discovery program in oncology, we have made a significant mark in bringing novel treatments to patients. Lupin’s MEK Inhibitor program successfully cleared early clinical stages, demonstrating our capabilities in delivering world class innovation. We are proud of the achievements of our team and the capabilities we have built which enable us to further our new drug discovery program. We are delighted to partner with Boehringer Ingelheim in developing treatments that will truly benefit patients in need”.

Dr. Raj Kamboj, President of Lupin’s Novel Drug Discovery and Development (NDDD) stated, “The success of our second NDDD program in Oncology has added to our confidence in bringing highly differentiated and best-in-class innovation from India for patients globally. Carrying forward our founder, Dr. Desh Bandhu Gupta’s dream in shaping true innovation, we have delivered a novel treatment from conceptualization to clinical stage development with promising results that can be a potential combination treatment for precision oncology.”

The collaboration has a strategic goal to focus on patients with gastrointestinal or lung cancers defined by KRAS mutations, sub-populations that currently need more effective therapeutic options. KRAS mutations occur in 1 in 7 of all human metastatic cancers making it the most frequently mutated cancer-causing gene, with mutation rates of more than 90 percent in pancreatic cancers, more than 40 percent in colorectal cancers and more than 30 percent in lung adenocarcinomas. Preclinical data has shown that the combination of Boehringer Ingelheim’s novel KRAS inhibitors with MEK inhibitors results in increased anti-tumor activity based on their complementary mechanisms of action in keeping KRAS-driven cancers in check.

Lupin’s MEK inhibitors developed as part of its oncology pipeline have shown pre-clinical activity as a single agent as well as in combination. Furthermore, they have also shown early clinical benefit in a small subset of patients. Lupin’s Novel Drug Discovery and Development team is focused on building a pipeline of highly differentiated and innovative new chemical entities in the therapeutic areas of oncology, immunology and metabolic disorders. Lupin’s NDDD activities were started with the vision to use cutting-edge research in bringing novel molecules that address unmet medical needs in multiple therapeutic areas to market globally.

Lupin will receive an upfront payment of $20 million and potential additional payments for successful achievement of defined clinical, regulatory and commercial milestones for a total deal value of more than $700 million. Additionally, Lupin will be entitled to receive double-digit royalties on the sales of the product.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/expansion-kras-cancer-program-mek-inhibitor

分享到:
第一至尊娱乐平台网免责声明:
1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
2、文章来源为均为其它网上真人斗牛的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供利来国际官方下载信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
3、本网站所载文章、数据、网友明升m88备用网站等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一至尊娱乐平台网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
发表评论

【发表评论】(网友评论内容只代表网友观点,与本站立场无关!)
 姓 名:
 评 分: 1分 2分 3分 4分 5分
 评论内容:
验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及高皇娱乐网站人民其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏明升m88备用网站稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  至尊娱乐男篮生死战是怎么回事?至尊娱乐男篮生死战具体
     瑞幸一年关147家外卖厨房怎么回事?小鹿茶不惜零
    [银行]  银行怎么了?六大银行上半年减员近3.5万人
     才半年时间!六大银行就减少3.5万人,还关了277
    [股票]  200亿"福布斯富豪"彻底凉了?公司美女总裁称病不
     暴风集团冯鑫事件 其多家企业为失信公司
    [基金]  2019年赚钱的公募基金都有谁 2019年赚钱基金排名
     大盘重回3000点 大涨底气在哪?基金最新解读来了
    [保险]  人保车险理赔时间规定
     职工医保和新农合医保哪个好?主要看这三点
    [期货]  油价调整蕞新消息:9月3日24时 本轮成品油上调板
     消息人士:至尊娱乐考虑大幅放开期货市场 以吸引海外
    [股评]  六大券商周四看好六大板块(9/5)
     券商评级:三大指数上涨 九股迎来掘金良机(9/5
    [港股]  小米120亿回购引争议:现金流承压 谁在抛售谁被
     No zuo no die!国泰航空19天蒸发超百亿,遭强烈
    [美股]  苹果2019年秋季发布会什么时候 相关产业链概念股
     百度广告困境:代理商无奈 广告主逃离
    [至尊娱乐平台登录]  突发!美元兑人民币逼近7.2!触及7.18345
     人民币对美元汇率中间价报7.0211元 下调75个基点
    [债券]  2018最火现金棋牌官网超越至尊娱乐 成美债最大海外持有国
     中城集团旗下多支债券违约 14亿银行存款被冻结
    [黄金]  黄金疯涨!六年前血战华尔街的“至尊娱乐大妈”解套
     刘智辛:欧美货币持稳,黄金日线三连阳,原油多
    [理财]  建国70周年币什么时候发行 2019建国70周年纪念币
     至尊娱乐女主播刘欣就热点问题对话CNBC
    [信托]  跌破8% 集合信托收益或继续下跌
     信托违约增多 预期收益9%的产品还能买吗?
    [房产]  2019年下半年房价走势会如何?房价会跌吗?
     至尊娱乐房企海外融资大幅缩水 环比下跌近八成
    [汽车]  特斯拉App宕机是怎么回事?至尊娱乐特斯拉App宕机事
     途观L七座版将于成都车展上市,与汉兰达正面交锋
  • 此栏目下没有推荐文章
  • | 设为至尊娱乐 | 加入收藏 | 关于我们 | 澳门足球 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 afinance.cn All Rights Reserved 版权所有·第一至尊娱乐平台网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客理财及投资指导,凡是以第一至尊娱乐平台网名义做股票推荐的行为均属违法!

    广告商的言论与行为均与第一至尊娱乐平台网无关!股市有风险,投资需谨慎。

    合作邮箱:申博平台 合作电话:利来国际官方下载 点击这里给我发消息

    条评论
    Sitemap